Bretonnière, Cédric Jozwiak, Mathieu Girault, Christophe Beuret, Pascal Trouillet, Jean-Louis Anguel, Nadia Caillon, Jocelyne Potel, Gilles Villers, Daniel Boutoille, David Guitton, Christophe Additional file 1: Figure S1. of Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study Bacteria involved in 136 episodes of meningitis. Figure S2. Glasgow Outcome Scale scores for the groups of patients who did or did not receive rifampin for community-acquired meningitis. Figure S3. Glasgow Outcome Scale scores for the groups of patients who did or not receive early rifampin (within the first 24 h of hospitalization) or not for community-acquired meningitis. Table S1. Comparison of patient characteristics, severity at ICU admission, 9pt?>microbiological data, and therapeutic measures between survivors and non-survivors after ICU admission for pneumococcal meningitis (n=76). Table S2. Factors associated with ICU mortality for a cohort of 76 patients admitted for pneumococcal meningitis. (PDF 157 kb) Table S 1. Comparison;French retrospective cohort ACAM-ICU study Bacteria;pneumococcal meningitis;Figure S 2. Glasgow Outcome Scale scores;Figure S 3. Glasgow Outcome Scale scores;community-acquired meningitis;ICU admission;PDF 157 kb 2015-08-26
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_Rifampin_use_in_acute_community-acquired_meningitis_in_intensive_care_units_the_French_retrospective_cohort_ACAM-ICU_study/4467848
10.6084/m9.figshare.4467848.v1